...
首页> 外文期刊>Journal of Medicinal Chemistry >Inhibitors of Multiple Mutants of Plasmodium falciparum Dihydrofolate Reductase and Their Antimalarial Activities
【24h】

Inhibitors of Multiple Mutants of Plasmodium falciparum Dihydrofolate Reductase and Their Antimalarial Activities

机译:恶性疟原虫二氢叶酸还原酶多个突变体的抑制剂及其抗疟活性

获取原文
获取原文并翻译 | 示例

摘要

Novel analogues of pyrimethamine (Pyr) and cycloguanil (Cyc) have been synthesized and tested as inhibitors of Plasmodium falciparum dihydrofolate reductase carrying triple (N51I+C59R+S108N, C59R+S108N+I164L) and quadruple (N51I+C59R+S108N+I164L) mutations responsible for antifolate resistance. The inhibitors were designed to avoid steric clash of the p-Cl group of the inhibitors with the side chain of Asn108, augmented by additional mutations of the resistant mutants. Cycloguanil derivatives were also designed to avoid steric clash with the side chain of Val16 in the A16V+S108T mutant. Many compounds have inhibition constants (Ki) at the low nanomolar level against the mutant enzymes and a number have good antimalarial activities against resistant P. falciparum parasites bearing multiple mutations in the S108N series and A16V+S108T mutant enzymes. These compounds in the Pyr and Cyc series exhibit low and moderate cytotoxicity to nontumor (Vero) and tumor (KB, BC) cell lines. Some of these inhibitors are therefore potential candidates for further development as antimalarials.
机译:已合成并测试了乙胺嘧啶(Pyr)和环鸟嘌呤(Cyc)的新型类似物,作为恶性疟原虫二氢叶酸还原酶的抑制剂,带有三重(N51I + C59R + S108N,C59R + S108N + I164L)和四重(N51I + C59R + S108N + I164L)抗叶酸抵抗的突变。设计抑制剂时,应避免抑制剂的p-Cl基与Asn108侧链发生空间冲突,因为抗性突变体的其他突变会加剧这种冲突。还设计了环鸟苷衍生物,以避免与A16V + S108T突变体中Val16的侧链发生空间冲突。许多化合物在低纳摩尔水平上对突变酶具有抑制常数(Ki),许多化合物对在S108N系列和A16V + S108T突变酶中带有多个突变的抗性恶性疟原虫寄生虫具有良好的抗疟活性。 Pyr和Cyc系列的这些化合物对非肿瘤(Vero)和肿瘤(KB,BC)细胞系表现出低度和中度的细胞毒性。因此,这些抑制剂中的某些是作为抗疟药进一步开发的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号